EP3752498A4 - Modulateurs de somatostatine et leurs utilisations - Google Patents

Modulateurs de somatostatine et leurs utilisations Download PDF

Info

Publication number
EP3752498A4
EP3752498A4 EP19751144.7A EP19751144A EP3752498A4 EP 3752498 A4 EP3752498 A4 EP 3752498A4 EP 19751144 A EP19751144 A EP 19751144A EP 3752498 A4 EP3752498 A4 EP 3752498A4
Authority
EP
European Patent Office
Prior art keywords
somatostatin modulators
somatostatin
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19751144.7A
Other languages
German (de)
English (en)
Other versions
EP3752498B1 (fr
EP3752498A1 (fr
Inventor
Jian Zhao
Shimiao Wang
Yunfei Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crinetics Pharmaceuticals Inc
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of EP3752498A1 publication Critical patent/EP3752498A1/fr
Publication of EP3752498A4 publication Critical patent/EP3752498A4/fr
Application granted granted Critical
Publication of EP3752498B1 publication Critical patent/EP3752498B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP19751144.7A 2018-02-12 2019-02-11 Modulateurs de somatostatine et leurs utilisations Active EP3752498B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862629377P 2018-02-12 2018-02-12
US201862673042P 2018-05-17 2018-05-17
US201862724421P 2018-08-29 2018-08-29
PCT/US2019/017529 WO2019157458A1 (fr) 2018-02-12 2019-02-11 Modulateurs de somatostatine et leurs utilisations

Publications (3)

Publication Number Publication Date
EP3752498A1 EP3752498A1 (fr) 2020-12-23
EP3752498A4 true EP3752498A4 (fr) 2021-11-03
EP3752498B1 EP3752498B1 (fr) 2023-06-28

Family

ID=67548490

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19751144.7A Active EP3752498B1 (fr) 2018-02-12 2019-02-11 Modulateurs de somatostatine et leurs utilisations

Country Status (5)

Country Link
US (1) US11608335B2 (fr)
EP (1) EP3752498B1 (fr)
JP (1) JP7365347B2 (fr)
MA (1) MA51840A (fr)
WO (1) WO2019157458A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019019168A2 (pt) 2017-03-16 2020-04-14 Crinetics Pharmaceuticals Inc moduladores de somatostatina e usos dos mesmos
WO2019157458A1 (fr) 2018-02-12 2019-08-15 Crinetics Pharmaceuticals, Inc. Modulateurs de somatostatine et leurs utilisations
TW202024095A (zh) 2018-09-18 2020-07-01 美商克林提克斯醫藥股份有限公司 生長抑制素(somatostatin)調節劑及其用途
BR112022002683A2 (pt) 2019-08-14 2022-07-05 Crinetics Pharmaceuticals Inc Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos
US11773076B2 (en) 2021-02-17 2023-10-03 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator
IL305015A (en) * 2021-02-17 2023-10-01 Crinetics Pharmaceuticals Inc Crystal forms of a somatostatin modulator
WO2024089668A1 (fr) * 2022-10-28 2024-05-02 Basecamp Bio Inc. Agonistes du récepteur 2 de la somatostatine et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2871179A1 (fr) * 2012-07-03 2015-05-13 ONO Pharmaceutical Co., Ltd. Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales
EP3053916A1 (fr) * 2013-09-30 2016-08-10 Ono Pharmaceutical Co., Ltd. Composé ayant une activité agoniste sur les récepteurs de la somatostatine et son utilisation médicale

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127343A (en) 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
CA2644929A1 (fr) * 2006-03-13 2008-05-02 Merck & Co., Inc. Agonistes de somatostatine
CN101506165B (zh) 2006-08-15 2012-07-04 霍夫曼-拉罗奇有限公司 苯基、吡啶和喹啉衍生物
EP2211619A1 (fr) 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. 1,2,4-oxadiazoles substitués et leurs analogues comme modulateurs des récepteurs cb2, utiles dans le traitement de la douleur et de maladies respiratoires et non respiratoires
EP2297131A2 (fr) 2008-06-25 2011-03-23 Envivo Pharmaceuticals, Inc. Composés phényles disubstitués
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
WO2011146324A1 (fr) 2010-05-18 2011-11-24 Merck Sharp & Dohme Corp. Composés spiroisoxazolines en tant qu'antagonistes sstr5
GB201008290D0 (en) 2010-05-18 2010-06-30 Syngenta Ltd Chemical compounds
EP3053961B1 (fr) 2013-10-02 2018-06-06 Kuraray Co., Ltd. Composition de résine, feuille multicouches, matériau d'emballage et conteneur
WO2018013676A1 (fr) 2016-07-14 2018-01-18 Crinetics Pharmaceuticals, Inc. Modulateurs de la somatostatine et leurs utilisations
US20200000816A1 (en) 2017-02-08 2020-01-02 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
BR112019019168A2 (pt) 2017-03-16 2020-04-14 Crinetics Pharmaceuticals Inc moduladores de somatostatina e usos dos mesmos
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2019157458A1 (fr) 2018-02-12 2019-08-15 Crinetics Pharmaceuticals, Inc. Modulateurs de somatostatine et leurs utilisations
TW202024095A (zh) 2018-09-18 2020-07-01 美商克林提克斯醫藥股份有限公司 生長抑制素(somatostatin)調節劑及其用途
BR112022002683A2 (pt) 2019-08-14 2022-07-05 Crinetics Pharmaceuticals Inc Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2871179A1 (fr) * 2012-07-03 2015-05-13 ONO Pharmaceutical Co., Ltd. Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales
EP3053916A1 (fr) * 2013-09-30 2016-08-10 Ono Pharmaceutical Co., Ltd. Composé ayant une activité agoniste sur les récepteurs de la somatostatine et son utilisation médicale

Also Published As

Publication number Publication date
EP3752498B1 (fr) 2023-06-28
US20210040087A1 (en) 2021-02-11
JP2021512889A (ja) 2021-05-20
US11608335B2 (en) 2023-03-21
WO2019157458A1 (fr) 2019-08-15
EP3752498A1 (fr) 2020-12-23
MA51840A (fr) 2021-05-19
JP7365347B2 (ja) 2023-10-19

Similar Documents

Publication Publication Date Title
EP3817822A4 (fr) Agents de dégradation de protéines et leurs utilisations
EP3737666A4 (fr) Agents de dégradation de protéines et utilisations associées
EP3484865A4 (fr) Modulateurs de la somatostatine et leurs utilisations
EP3684365A4 (fr) Agents de dégradation des protéines et utilisations de ces derniers
EP3596062A4 (fr) Modulateurs de la somatostatine et leurs utilisations
EP4041362A4 (fr) Dispositifs de gestion de fil-guide et procédés associés
EP3752612A4 (fr) Composés modifiés et leurs utilisations
EP3746124A4 (fr) Composés et leurs utilisations
EP3853218A4 (fr) Modulateurs de somatostatine et leurs utilisations
EP3752498A4 (fr) Modulateurs de somatostatine et leurs utilisations
EP3317277A4 (fr) Modulateurs de la somatostatine et leurs utilisations
EP3658560A4 (fr) Modulateurs de la somatostatine et utilisations de ces derniers
EP3611233A4 (fr) Encre et ensemble d'encres
EP3841096A4 (fr) Dérivés de pyridinylméthylènepipéridine et leurs utilisations
EP3870173A4 (fr) Modulateurs et inhibiteurs de wdr5
EP3317278A4 (fr) Modulateurs de somatostatine et leurs utilisations
EP3838900A4 (fr) Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées
EP3902530A4 (fr) Nanovaccins polymères et leurs utilisations
ZA202105847B (en) Mtroc modulators and uses thereof
EP3774737A4 (fr) Modulateurs de calpaïne et leurs utilisations thérapeutiques
EP3808357A4 (fr) Composition et ses applications
EP3618578A4 (fr) Composition et élément électroluminescent faisant appel à ladite composition
EP3853216A4 (fr) Composés substitués par pyridinyle et leurs utilisations
EP3813861A4 (fr) Polypeptides associés à l'héparine et leurs utilisations
EP3768269A4 (fr) Composés et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20200818

Extension state: MD

Effective date: 20200818

A4 Supplementary search report drawn up and despatched

Effective date: 20210930

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 471/04 20060101ALI20210924BHEP

Ipc: C07D 401/14 20060101AFI20210924BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220811

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230203

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1582607

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019031753

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230928

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20230628

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1582607

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231221

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231030

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231028

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231212

Year of fee payment: 6

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230628

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231220

Year of fee payment: 6

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT